Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2137653 | 1.00 | KDM4E (0.46) | KDM4EUBE2NHTR6HTR2AHTR2C | |
| SCHEMBL2137327 | 0.84 | KDM4E (0.43) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL2137329 | 0.84 | KDM4E (0.43) | KDM4EUBE2NHTR6CA2CA9 | |
| SCHEMBL2134863 | 0.82 | KDM4E (0.46) | KDM4EUBE2NHTR6HTR2ACA2 | |
| SCHEMBL2134859 | 0.82 | KDM4E (0.46) | KDM4EUBE2NHTR6HTR2ACA2 | |
| SCHEMBL2945658 | 0.81 | CA2 (0.50) | KDM4EUBE2NHTR6HTR2AHTR2C | |
| SCHEMBL2945655 | 0.81 | CA2 (0.50) | KDM4EUBE2NHTR6HTR2AHTR2C | |
| SCHEMBL2138689 | 0.80 | KDM4E (0.66) | KDM4EUBE2NHTR6HTR2AHTR2C | |
| SCHEMBL2139504 | 0.80 | PTGDR2 (0.48) | KDM4EUBE2NHTR6HTR2ACA2 | |
| SCHEMBL2139508 | 0.80 | PTGDR2 (0.48) | KDM4EUBE2NHTR6HTR2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | KDM4E 837/4885UBE2N 4408/4885HTR6 1715/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | KDM4E 830/4885UBE2N 4410/4885HTR6 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.